| Literature DB >> 28281164 |
Eun Young Ze1, Beom Jin Kim2, Hyun Kang3, Jae Gyu Kim1.
Abstract
BACKGROUND: To investigate the association between abdominal fat distribution represented by the visceral fat area (VFA) to subcutaneous fat area (SFA) ratio, and erosive esophagitis (EE).Entities:
Keywords: Erosive esophagitis; Gastroesophageal reflux disease; Subcutaneous fat area; Visceral fat area
Mesh:
Year: 2017 PMID: 28281164 PMCID: PMC5397435 DOI: 10.1007/s10620-017-4467-4
Source DB: PubMed Journal: Dig Dis Sci ISSN: 0163-2116 Impact factor: 3.199
Baseline demographic and clinical characteristics
| Variables | |
|---|---|
| Number of subjects | 728 |
| Age (mean ± SD, years) | 47.15 ± 8.35 |
| Sex | |
| Male | 629 (86.4) |
| Female | 99 (13.6) |
| BMI (kg/m2) (mean ± SD) | 24.66 ± 2.85 |
| Metabolic syndrome | |
| Yes | 65 (8.9) |
| No | 663 (91.1) |
| Blood pressure (mean ± SD, mmHg) | 124.30 ± 14.72 |
| HDL cholesterol (mg/dl) | 49.09 ± 9.21 |
| Triglyceride (mg/dl) | 41.78 ± 36.08 |
| Fasting glucose (mg/dl) | 101.02 ± 19.39 |
| Erosive esophagitis | |
| Yes | 65 (8.9) |
| No | 663 (91.1) |
| Hiatal hernia | |
| Yes | 11 (1.5) |
| No | 717 (98.5) |
| VF area (cm2) | 2886.97 ± 5260.61 |
| SF area (cm2) | 3627.27 ± 7764.85 |
| VF/SF ratio (mean ± SD) | 1.02 ± 0.49 |
BMI body mass index; high blood pressure, ≥130/85 mmHg or documented use of antihypertensive therapy, LDL low-density lipoprotein, HDL high-density lipoprotein, SF subcutaneous fat, VF visceral fat
Comparison of clinical characteristics between subjects with reflux esophagitis and those without
| Subjects with reflux esophagitis ( | Subjects without reflux esophagitis ( |
| |
|---|---|---|---|
| Age (range, years) | 46 (42–50) | 48 (42–53) | 0.260 |
| Sex | 0.003 | ||
| Male (%) | 1 (1.5) | 98 (14.8) | |
| Female (%) | 64 (98.5) | 565 (85.2) | |
| BMI (kg/m2) | 25.80 (23.55–27.65) | 24.40 (22.70–26.20) | 0.002 |
| Metabolic syndrome | <0.001 | ||
| Yes (%) | 20 (30.8) | 91 (13.7) | |
| No (%) | 45 (69.2) | 572 (86.3) | |
| HDL cholesterol (mg/dl) | 46 (40–52) | 48 (43–54) | 0.066 |
| Triglyceride (mg/dl) | 45 (26–65) | 29 (20–49) | <0.001 |
| High blood pressure | 0.006 | ||
| Yes (%) | 35 (53.8) | 242 (36.6) | |
| No (%) | 30 (46.2) | 420 (63.4) | |
| Fasting glucose (mg/dl) | 98.00 (93.50–107.00) | 97.00 (91.00–105.00) | 0.307 |
| Hiatal hernia | 6 (9.2) | 5 (0.8) | <0.001 |
| VF area (cm2) | 1595.00 (841.50–1936.50) | 1426.00 (998.00–1950.00) | 0.927 |
| SF area (cm2) | 1226.92 (707.58–2054.67) | 1514.46 (945.68–2772.09) | 0.010 |
| VF/SF | 1.30 (0.87–1.63) | 0.92 (0.67–1.29) | <0.001 |
BMI body mass index; high blood pressure, ≥130/85 mmHg or documented use of antihypertensive therapy, LDL low-density lipoprotein, HDL high-density lipoprotein, NS nonspecific, SF subcutaneous fat, VF visceral fat
Logistic regression analysis of covariables for erosive esophagitis
| Variable | OR (95% CI) | Univariate analysis ( | OR (95% CI) | Multivariate analysis ( |
|---|---|---|---|---|
| Age (years) | ||||
| <65 ( | 1 | |||
| ≥65 ( | 1.88 (0.41–8.68) | 0.326 | ||
| Sex | ||||
| Female ( | 1 | |||
| Male ( | 0.09 (0.01–0.66) | 0.003 | 0.19 (0.03–1.40) | 0.191 |
| BMI (kg/m2) | ||||
| <25 ( | 1 | |||
| ≥25 ( | 2.25 (1.33–3.81) | 0.002 | 1.64 (0.93–2.87) | 0.086 |
| Metabolic syndrome | ||||
| No ( | 1 | |||
| Yes ( | 2.79 (1.58–4.95) | <0.001 | 0.82 (0.33–2.01) | 0.819 |
| HDL cholesterol (mg/dl) | ||||
| <40 ( | 1 | |||
| ≥40 ( | 1.37 (0.69–2.72) | 0.371 | ||
| Triglyceride (mg/dl) | ||||
| <150 ( | 1 | |||
| ≥150 ( | 6.06 (1.97–18.65) | 0.005 | 4.74 (1.35–16.62) | 0.015 |
| High blood pressure | ||||
| No ( | 1 | |||
| Yes ( | 2.04 (1.22–3.41) | 0.006 | 1.72 (0.97–3.07) | 0.065 |
| Fasting glucose (mg/dl) | ||||
| <110 ( | 1 | |||
| ≥110 ( | 0.93 (0.46–1.87) | 0.826 | ||
| Hiatal hernia | ||||
| No ( | 1 | |||
| Yes ( | 13.38 (3.97–45.17) | 0.001 | 12.90 (3.57–46.65) | <0.001 |
| VF/SF ratio | ||||
| <1.165 ( | 1 | |||
| ≥1.165 ( | 2.77 (1.65–4.65) | <0.001 | 2.04 (1.18–3.51) | 0.010 |
BMI body mass index, CI confidence interval; high blood pressure, ≥130/85 mmHg or documented use of antihypertensive therapy, LDL low-density lipoprotein, HDL high-density lipoprotein, VF visceral fat, SF subcutaneous fat
Fig. 1Association between erosive esophagitis and VF/SF ratio. The incidence of erosive esophagitis was higher in the group with the higher VFA/SFA ratio (P for trend <0.001)
Fig. 2AUROC of VF/SF ratio in the identification of erosive esophagitis. Receiver-operating characteristic (ROC) curve indicated that a VFA/SFA ratio ≥1.165 had a good accuracy to predict erosive esophagitis (AUROC = 0.643). AUROC area under the receiver operator characteristic curve
Association between visceral fat/subcutaneous fat ratio and severity of erosive esophagitis
| Normal | LA-A | LA-B | LA-C, D | |
|---|---|---|---|---|
| No. of subjects (%) | 663 (91.1) | 50 (6.9) | 14 (1.9) | 1 (0.1) |
| VF/SF (mean ± SD) | 1.00 ± 0.49 | 1.23 ± 0.53 | 1.27 ± 0.47 | 1.56 |
|
| 0.002 | |||
VF visceral fat, SF subcutaneous fat
Severity of erosive esophagitis according to visceral fat/subcutaneous fat ratio
| Normal | LA-A | LA-B | LA-C, D | |
|---|---|---|---|---|
| No. of subjects (%) | 663 (91.1) | 50 (6.9) | 14 (1.9) | 1 (0.1) |
| VF/SF <1.165 | 449 (94.1) | 24 (5.0) | 4 (0.9) | 0 (0.0) |
| VF/SF ≥1.165 | 214 (85.3) | 26 (10.3) | 10 (4.0) | 1 (0.4) |
|
| <0.001 | |||
|
| <0.001 | |||
VF visceral fat, SF subcutaneous fat